No connection

Search Results

HQL vs JPM

HQL
Abrdn Life Sciences Investors
BULLISH
Price
$17.56
Market Cap
$534.0M
Sector
Financial Services
AI Confidence
75%
JPM
JPMorgan Chase & Co.
NEUTRAL
Price
$313.68
Market Cap
$846.01B
Sector
Financial Services
AI Confidence
85%

Valuation

P/E Ratio
HQL
6.29
JPM
15.68
Forward P/E
HQL
--
JPM
13.42
P/B Ratio
HQL
1.01
JPM
2.47
P/S Ratio
HQL
275.47
JPM
5.03
EV/EBITDA
HQL
--
JPM
--

Profitability

Gross Margin
HQL
100.0%
JPM
0.0%
Operating Margin
HQL
-346.83%
JPM
41.06%
Profit Margin
HQL
4415.74%
JPM
33.91%
ROE
HQL
17.59%
JPM
16.13%
ROA
HQL
-0.43%
JPM
1.35%

Growth

Revenue Growth
HQL
-69.9%
JPM
2.5%
Earnings Growth
HQL
259.4%
JPM
-3.6%

Financial Health

Debt/Equity
HQL
--
JPM
--
Current Ratio
HQL
0.73
JPM
--
Quick Ratio
HQL
0.71
JPM
--

Dividends

Dividend Yield
HQL
12.76%
JPM
1.91%
Payout Ratio
HQL
65.23%
JPM
28.97%

AI Verdict

HQL BULLISH

HQL presents as a deep-value opportunity, anchored by a stable Piotroski F-Score of 6/9 and a significant valuation gap, with a current price of $17.56 trading well below its Graham Number ($33.01) and Intrinsic Value ($82.31). While the company exhibits severe operational anomalies—specifically a -69.90% revenue collapse and a deeply negative operating margin—the massive earnings growth and low P/E ratio (6.29) suggest the entity is benefiting from significant investment gains rather than core fee income. The high dividend yield of 12.76% is supported by a sustainable payout ratio, though the bearish technical trend (10/100) suggests a period of consolidation or price correction is underway.

Strengths
Extreme undervaluation relative to Graham Number ($33.01) and Intrinsic Value ($82.31)
Very low P/E ratio (6.29) compared to the sector average of 36.83
Strong dividend yield of 12.76% with a manageable payout ratio (65.23%)
Risks
Severe revenue decline (-69.90% YoY) indicating a collapse in core business growth
Poor operational efficiency with an operating margin of -346.83%
Liquidity risk evidenced by a current ratio of 0.73 (below 1.0)
JPM NEUTRAL

JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.

Strengths
Strong profitability with a 33.91% profit margin
Robust Return on Equity (ROE) of 16.13%
Conservative dividend payout ratio of 28.97%
Risks
Very low Piotroski F-Score (2/9) suggesting deteriorating financial health
Significant overvaluation relative to Intrinsic Value ($140.07)
Negative Year-over-Year earnings growth (-3.60%)

Compare Another Pair

HQL vs JPM: Head-to-Head Comparison

This page compares Abrdn Life Sciences Investors (HQL) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile